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Plasmodium vivax threatens nearly half the world’s population and is a significant impediment to achievement of
the millennium development goals. It is an important, but incompletely understood, cause of anaemia. This review
synthesizes current evidence on the epidemiology, pathogenesis, treatment and consequences of vivax-associated
anaemia. Young children are at high risk of clinically significant and potentially severe vivax-associated anaemia,
particularly in countries where transmission is intense and relapses are frequent. Despite reaching lower densities
than Plasmodium falciparum, Plasmodium vivax causes similar absolute reduction in red blood cell mass because it
results in proportionately greater removal of uninfected red blood cells. Severe vivax anaemia is associated with
substantial indirect mortality and morbidity through impaired resilience to co-morbidities, obstetric complications
and requirement for blood transfusion. Anaemia can be averted by early and effective anti-malarial treatment.
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Plasmodium vivax threatens approximately 2.8 billion
people globally and, because of its particular biological
characteristics, will be more difficult to eradicate than
Plasmodium falciparum [1-9]. Over recent years, case
series [10-13], surveillance studies [14-17] and reviews
[4,18-24] have linked vivax malaria with a number of se-
vere manifestations similar to those found in P. falciparum
infection; observations that challenge the notion that vivax
malaria is a benign disease. The causative role of P. vivax
in some of these severe manifestations remains to be
proven and many are sufficiently rare that they are unlikely
to represent significant public health problems. Anaemia,
on the other hand, is a common and frequently severe con-
sequence of vivax infection [14-16,25-27]. This review
explores the epidemiology, pathophysiological mechanisms,
relationship to transmission dynamics and consequences of
anaemia caused by vivax malaria (highlighting similarities
and differences as compared with P. falciparum). The
impact of anti-malarial treatment on haematological
recovery is also described.* Correspondence: nicholas.douglas@gmail.com
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Endemic P. vivax is transmitted throughout the tropics
in much the same geographical pattern as P. falciparum
[1,8]. The major exception is West Africa where P. vivax
is largely absent. This has been attributed to selection
over many millennia of individuals lacking the Duffy red
blood cell surface antigen - an important mediator of
P. vivax red cell invasion [2,28]. Menard and colleagues’
recent discovery of vivax malaria in Duffy negative Mala-
gasy people suggests that P. vivax may have escaped its
dependence on the Duffy antigen in certain regions [29].
Where P. falciparum and P. vivax co-exist, both the inci-
dence of infection and severity of haematological morbidity
attributable to P. vivax tends to peak at a younger age than
for falciparum malaria and in many regions, before the end
of the second year of life [16,27,30-32]. This pattern prob-
ably reflects greater parasite exposure through frequent
relapse and consequently more rapid acquisition of
immunity to vivax malaria. In tropical regions, relapses
may occur as often as every three weeks [33,34]. In Papua,
Indonesia, an area of comparatively high-level P. vivax
transmission, approximately a quarter of infants hospita-
lized with vivax malaria have severe anaemia (haemoglobin
less than 5 g/dL), whereas in individuals 45 years or older
this proportion decreases to less than 5% [16]. Infants with
vivax malaria in this region have 2.4-fold greater odds of
severe anaemia than those with falciparum malaria [27].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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P. vivax malaria than males [16] and in one large analysis
were more likely to present with anaemia (unpublished
data). Both phenomena may be, at least partially,
explained by the fact that post-pubertal women have a
lower mean haemoglobin concentration than men and
therefore have a greater chance of being tipped over the
threshold for anaemia following a haematological insult.
Pregnant women with P. vivax infection have a ~2-fold
higher risk of moderate anaemia than uninfected preg-
nant women [35-37]. Whether the haematological
impact of vivax malaria in pregnancy is greater than in
non-pregnant women of child-bearing age is unknown.
Several red blood cell and haemoglobin variants have
been associated with reduced susceptibility to anaemia
caused by falciparum malaria, the best known being
sickle cell anaemia. Hypothesized mechanisms for this
protection include reduced red blood cell invasion, rela-
tive inhibition of intracellular parasite replication, more
efficient removal of infected red blood cells by the spleen
and more efficient presentation of parasite antigens to
the immune system [38-40]. The high erythrocyte counts
and relative microcytosis seen in conditions such as
alpha-thalassaemia result in a lower proportional reduc-
tion in haemoglobin with falciparum malaria [41]. Both
alpha- and beta-thalassaemia have been associated with
an increased risk of P. vivax parasitaemia in cross
sectional studies but their effect on vivax anaemia is un-
known [42-44]. Preliminary work suggests South-East Asian
ovalocytosis may protect against P. vivax parasitaemia and
vivax-associated anaemia [45,46] whereas the effects of
Gerbich blood group are unclear [47]. Glucose-6-phosphate
dehydrogenase deficiency is associated with protection
against clinical disease and reduced parasite density in
P. vivax infections [48,49]. The rarity of such polymorph-
isms in migrant Highland Papuan populations has been
hypothesized to contribute to the higher risk of severe
anaemia from P. vivax in Southern Papua compared with
elsewhere in New Guinea [22].
Gastrointestinal helminth infections may cause
anaemia through chronic blood loss, but the interaction
with malarial anaemia is complex. In Africa, hookworm
and P. falciparum malaria coinfection has been shown to
cause an additive reduction in haemoglobin in children
and pregnant mothers when compared with monoinfec-
tion with either parasite alone [50]. Helminthiasis may
also be a risk factor for P. falciparum parasitaemia but
evidence is conflicting [51,52]. Few studies have
addressed the effect of intestinal helminthiasis on the
risk of P. vivax infection and vivax-associated anaemia.
Boel and colleagues showed a positive association
between Ascaris lumbricoides infection during pregnancy
and risk of vivax malaria [53]. Another small study found
that the reduction in haemoglobin associated withP. vivax infection in children between five and 14 years
of age was attenuated by coinfection with hookworm,
A. lumbricoides and Trichuris trichuria [54].
The haematological effects of chronic blood loss
caused by intestinal helminthiasis are exacerbated by nu-
tritional iron deficiency which in turn may interact with
the haematological effects of P. vivax malaria. Iron defi-
ciency is protective against P. falciparum infection
whereas iron supplementation increases the risk of fal-
ciparum malaria and high parasitaemia infections
[55,56]. The evidence for a link between iron supplemen-
tation and morbidity associated with vivax malaria is
conflicting. One large prospective study from Thailand
showed that pregnant women given supplemental iron
and folate were at increased risk of P. vivax infection
compared to those who did not receive supplementation
[57]. A randomized controlled trial from Peru showed
that iron plus zinc reduced vivax-associated morbidity in
children under five years of age, but iron supplementa-
tion increased morbidity in those over five years [58]. In
Papua New Guinea, 16 weeks of supplemental iron in
prepubescent school children provided an overall haem-
atological benefit compared with placebo and had no
effect on the risk of morbidity associated with vivax
malaria [59]. Large, multi-centre trials including both
pre- and post-pubescent participants are required to
firmly establish whether an association between iron
status and vivax anaemia exists.
Pathophysiology and mechanisms
The primary target of human Plasmodium species is the
red blood cell. Plasmodium vivax has a very strong pre-
dilection for red blood cells that have emerged from the
bone marrow within the last 14 days, in particular reticu-
locytes, whereas P. falciparum has only a moderate
predilection for young red blood cells and significant
ability to infect older cells [60-62]. The natural history of
erythrocytes infected by either species is to host the
replicating parasite for approximately 48 hours before
bursting and releasing daughter merozoites. The range of
peripheral parasitaemia in P. vivax infections is lower than
in symptomatic P. falciparum malaria and parasitaemia
>2% is rare [9]. Despite this, mathematical models suggest
that premature death of infected reticulocytes due to
P. vivax infection should be sufficient to lead to extreme
anaemia over a period of several months by choking the
supply of mature red blood cells [63-65]. Direct evidence
from two malariatherapy patients studied in detail shows
that severe anaemia may develop much more rapidly than
this and that the proportion of infected reticulocytes after
two to three weeks of vivax malaria can be less than 10%
[60]. These observations suggest that other mechanisms of
anaemia are likely to be important. In P. falciparum
malaria, these include increased removal of infected, and
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culation, compounded, in subacute and chronic forms,
by impaired erythropoiesis [66-70]. The same general
processes appear to be important in vivax malaria but
many of the cellular mechanisms differ (see Figure 1
[9,27,60,61,63,64,66-104]).
Removal of red blood cells from circulation
Although parasitaemia is typically lower in vivax compared
with falciparum infections, the absolute number of red
blood cells removed from circulation, and hence the degree
of anaemia resulting from infection by the two species, is
often similar [16,26,105]. This is because in P. vivax malaria,
approximately 34 non-infected cells are cleared for every
one infected cell [73] whereas in P. falciparum malaria, this
ratio is closer to 8 to 1 [67,70]. These figures are derived
from observations in non-immune adults treated for neuro-
syphilis [67,73] and Thai patients over 5 kg in weight [70].
There are no data on the proportional removal of unin-
fected red blood cells in infants, the age group bearing the
greatest burden of anaemia due to vivax malaria. Although
removal of uninfected red blood cells is an important com-
ponent of vivax-associated anaemia, the mechanisms of
removal are not fully understood.
As in falciparum malaria, vivax-infected erythrocytes
adhere to uninfected red blood cells (rosetting) [106,107]
but unlike falciparum-infected cells, they have limited
propensity to adhere to endothelial cells and, therefore,
sequestration in the deep microvasculature is not a
major factor in the pathogenesis of vivax malaria
[108,109]. Erythrocytes parasitized by P. falciparum
become less deformable than uninfected red cells and
have reduced capacity to pass through narrow inter-
endothelial slits in the wall of splenic sinuses (mean
dimensions 1.89 × 0.65 μm) [85-87,110]. Vivax-infected
cells become more deformable as the parasite matures
and are thought to retain the ability to squeeze through
splenic slits [81,110,111]. In falciparum malaria, red
blood cell sequestration reduces the proportion of para-
sitized red blood cells that traverse the spleen. Increased
deformability of infected red blood cells in vivax malaria
may limit the proportion of red cells that are removed
during passage through the splenic microcirculation.
Thus, it appears that P. falciparum and P. vivax have
evolved two different means of escaping splenic filtra-
tion. In both vivax and falciparum malaria, parasitized,
and possibly non-parasitized, red cells are hypothesized
to be more fragile than red cells in non-infected indivi-
duals and more prone to damage from shear stresses
[72,81,110,112]. This process is potentially a more im-
portant cause of red cell loss in falciparum malaria since
in this disease, major sequestration in the microvascula-
ture impedes the passage of circulating erythrocytes and
erythrocyte rosettes [82].In addition to these mechanical processes, activation of
the innate, cell-mediated and humoral immune systems
in response to the presence of P. vivax antigens enhances
the detection and removal of infected and abnormal un-
infected red blood cells [69,75,113]. The non-specific
immune response for a given parasitaemia is greater for
P. vivax than P. falciparum and may partially explain the
greater proportional removal of non-parasitized cells and
lower fever threshold in vivax malaria [114-116]. This is
a relatively weak speculation however since in severe
falciparum malarial anaemia, cytokine levels are generally
lower than in cerebral or uncomplicated attacks [96,97]
and cytokine concentrations have not been found to
correlate with the degree of anaemia in P. vivax infec-
tions [105]. Macrophage hyperplasia and increased
phagocytic activity in both falciparum and vivax malaria
results in a highly oxidative environment and may
contribute to the shortened lifespan of non-infected ery-
throcytes [75,117-121]. To compound the problem,
reduced glutathione, which is necessary for protecting
red cells against damaging oxygen species, is reported to
be depleted in vivax malaria [93,122]. Infection with
P. falciparum causes altered expression of complement
components and deposition of parasite proteins on
infected and uninfected red blood cells [88,92] (the latter
sometimes associated with presence of specific immuno-
globulins); facilitating opsonization and complement-
mediated phagocytosis [89,91,123]. It is unknown
whether these processes also occur in vivax anaemia.
Whatever the mechanisms leading to red blood cell
alteration, the spleen is the most important site for the
filtration, retention and phagocytosis of non-sequestered
erythrocytes parasitised or altered by P. falciparum
[87,124-127]. Splenic activity limits parasite density
thereby reducing the risk of severe malaria. However, the
more stringent the splenic clearance, the greater the like-
lihood of severe anaemia [124,125,128]. This may explain
why concomitant severe malarial anaemia with spleen
enlargement and cerebral malaria is relatively unusual
with cerebral manifestations being more common in
acute, fulminant infections and anaemia being more
likely in chronic infections [27,76,128,129]. The role of
the spleen in vivax malaria is poorly understood though
splenic enlargement in this infection appears to be simi-
lar to falciparum malaria [130,131]. Indeed vivax malaria
carries a very low but well-known risk of splenic rupture;
considered greater than for falciparum malaria [132,133].
In 1974, Littman described a single patient with hereditary
spherocytosis who developed severe anaemia secondary to
vivax malaria. A relapse five months later after a splenec-
tomy did not cause anaemia suggesting that the spleen was
the primary site of red blood cell removal (though the effect
of strain specific immunity could not be excluded) [134]. A
study from Papua showed that plasma haemoglobin
Risk factors 
for anaemia 
In P. falciparum-infected subjects: 
young age, splenomegaly, chronic 
infection, recrudescence [70,71] 
Anaemia or decreased haemoglobin 
In P. vivax-infected subjects: 
young age, splenomegaly, chronic 
infection, repeated attacks [27,72]
Key data on 
major 
processes 
In P. falciparum 
malaria: 8 
uninfected RBC 
lost for 1 infected 
RBC in peripheral 
blood [67,70]  
Red blood cell 
loss 
In P. vivax 
malaria: 34 
uninfected RBC 
lost for 1 infected 
RBC in peripheral 
blood [73]
In P. falciparum 
malaria: 
reticulocytes not 
high enough for 
level of anaemia 
[71] 
Impaired red 
blood cell 
production 
In P. vivax 
malaria: 
reticulocytes low 
during the first 10 
days then 
appropriately 
increased during 
3–6 weeks [60,61]
Intravascular haemolysis 
RBC breaks in the 
bloodstream before being 
phagocytosed
Extravascular haemolysis 
RBC phagocytosed as intact 
cell
Dyserythropoiesis 
Progenitors proliferate but do 
not exit from the bone 
marrow
Bone marrow insufficiency 
Progenitors do not proliferate 
enough
↓ ↓ ↓ ↓
Markers of 
processes 
Low haptoglobin & 
haemopexin 
High LDH & α-HBDH [71]  
High annexin V & neopterin 
Low CD35 & CD55 [71]  
In vitro phagocytosis of 
uninfected RBC [71]  
Accumulation & phagocytosis 
of infected & uninfected RBC 
in the spleen [74] & bone 
marrow [66]  
Phagocytosis of infected & 
uninfected RBC in the spleen 
[75] & bone marrow [76]
Nuclear abnormalities of 
erythroblasts more frequent in 
children with chronic 
infection [66,68,69]  
0.23-15.1% of erythroblasts 
with marked nuclear 
abnormalities in 6 of 9 adults 
with acute infection [76]  
Phagocytosis of erythroblasts
(also in falciparum malaria)
[69]
Decreased cellularity at acute 
stage in 3/11 adults [77]  
Rare observations of 
parasitized erythroblasts 
[78,79]. Not seen in 9 adults 
[76]  
No data in children or in 
severe anaemia. Proportion of 
erythroblasts normal or 
increased in 8 of 9 adults with 
acute infection [76]
↓ ↓ ↓ ↓
Identified or 
suspected 
cellular 
mechanisms 
Rupture of sequestered 
schizonts [80]  
Rupture of circulating 
schizonts including parasite-
harbouring reticulocytes 
[63,64]. Intravascular 
haemolysis due to rupture of 
schizonts lower in P. vivax
than in P. falciparum as 
parasitaemia is lower in P. 
vivax [9]  
Rupture of uninfected RBC 
(increased fragility) [81]
Mechanical retention of 
uninfected RBC in the spleen 
due to decreased 
deformability [82,83]  
Mechanical retention of rings 
in the spleen due to decreased 
deformability [84-87]  
Phagocytosis & opsonization 
of uninfected RBC decorated 
with RSP-2/RAP-2 [88], 
complement [89-91], 
immunoglobulins [92] or low 
levels of CD55 [104]  
Oxidative stress on uninfected 
RBC & infected RBC [93]
(also in falciparum malaria) 
[94,95]  
Increased osmotic fragility & 
Heinz body formation of 
uninfected RBC [72]
Macrophage activation by 
cytokines or parasite products 
enhancing phagocytosis of 
progenitors (including 
erythroblasts) [69] although 
cytokine levels are generally 
lower in severe malarial 
anaemia than in cerebral or 
uncomplicated attacks [96,97]  
Toxic effect of parasite 
products (eg haemozoin) on 
progenitors (including 
erythroblasts) (also in 
falciparum malaria) [69]
RAP-2 on the surface of 
erythroblasts & phagocytosis 
in vitro [98]  
Impaired iron utilization (also 
in falciparum malaria) [99]
Inappropriate bone marrow 
response to appropriate EPO 
levels in children [100,101] 
though possibly not in adults 
[102,103]  
Figure 1 Comparative pathogenic mechanisms of anaemia associated with P. vivax and P. falciparum malaria (mechanisms in red font
relate to vivax malaria and mechanisms in black relate to falciparum malaria). Abbreviations: RBC; red blood cell, CD35; complement
receptor 1, CD55; decay accelerating factor, LDH; lactate dehydrogenase, α-HBDH; alpha-hydroxybutyrate dehydrogenase, RSP-2; ring surface
protein 2, RAP-2; rhoptry-associated protein-2, EPO; erythropoietin.
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were not increased compared to controls and were signifi-
cantly lower than in falciparum malaria (unpublished data).
This suggests that in adults with vivax malaria, the degree
of intravascular haemolysis may be less than in falciparum
malaria and that a greater proportion of uninfected red
blood cells undergo extravascular removal.
Increased removal and destruction of both infected and
uninfected red cells in vivax malaria is most prominent
during the early stages of infection however enhanced re-
moval of uninfected cells persists for five weeks or more
after effective treatment of blood-stage infection [135,136].
In chronic, asymptomatic vivax parasitaemia, common in
vivax-endemic areas, removal of both infected and unin-
fected red cells is likely to persist for the duration of
infection.
Impaired production of red blood cells
Patients with vivax or falciparum malaria have bone mar-
row abnormalities reflecting impaired erythropoiesis. In the
earliest stages of both infections, the typical marrow finding
is of decreased cellularity [69,77]. In those with more
chronic infections, marrow cellularity tends to be normal or
increased but there is ineffective erythropoiesis [66,68,76],
as indicated by impaired iron utilization [69,99], presence of
morphologically abnormal erythroblasts as a result of cellu-
lar injury [76], and phagocytosis of erythroblasts by marrow
macrophages [69,76].
The exact mechanisms and functional importance of
impaired erythropoiesis in vivax malaria are unclear. Using
electron microscopy, Ru and colleagues have shown
parasitization and subsequent degradation of erythroblasts
in two patients with uncomplicated vivax malaria [78]. Yoeli
demonstrated morphologically normal, but non-pigmented,
intracellular P. vivax parasites in a sternal tap specimen but
not in peripheral blood smears in a single patient with vivax
malaria [79]. Wickramasinghe did not find any P. vivax
parasites in the marrows of nine Thai adults with uncompli-
cated P. vivax infections [76]. Because of the absence of any
bone marrow data in children, or at any age with severe
vivax-associated anaemia, the importance of P. vivax
parasitization of erythroblasts in severe vivax anaemia is
not known. Hypoxia of the bone marrow resulting from ob-
struction of marrow sinusoids by parasitized red blood cells
and inadequate erythropoietin production or response have
been hypothesized to contribute to impaired erythropoiesis
in P. falciparum infections [76,102,103,137-139]. In vivax
malaria, hypoxia of the bone marrow is unlikely to be sig-
nificant as there is minimal schizont sequestration. Erythro-
poietin metabolism is yet to be studied in this disease.
Wickramasinghe and colleagues proposed that P. vivax
has a directly toxic effect on erythroblasts or their pre-
cursors [76]. Alternatively P. vivax may exert its effect
on bone marrow macrophages leading to increasedphagocytic activity and/or release of locally cytotoxic
molecules damaging surrounding haematopoietic cells
[76]. Whatever the cause, some degree of impaired
erythropoiesis has been shown to persist for at least two
weeks after treatment of vivax malaria and therefore the
effects of these putative factors must be long-lasting [76].
Effects of transmission intensity, relapse patterns, and
strain diversity
Since a significant proportion of the anaemia of vivax
malaria, at least in the acute phase, can be explained by re-
moval of uninfected red cells in response to immune system
activation, the magnitude of the immune response (of
which intensity of symptoms can be taken as a proxy) is
likely to be an important determinant of haematological im-
pairment. Untreated primary sporozoite-induced infection
in non-immune adult patients with neurosyphilis typically
results in paroxysmal fever lasting 3–8 weeks followed by
an extended period of increasing clinical ‘tolerance’ to per-
sistent parasitaemia [140]. Anti-parasite immunity that sup-
presses parasitaemia to subpatent levels takes significantly
longer to develop, in many cases more than 200 days [141].
Collins and colleagues have reviewed the natural history of
haemoglobin changes associated with untreated Plasmo-
dium vivax infection in adult neurosyphilis patients [73].
There was an exponential decay in mean haemoglobin
concentrations during the first 4–5 weeks followed by a
gradual climb in concentrations coinciding with develop-
ment of parasite tolerance (see Figure 2). With persistent
infection, mean haemoglobin levels had still not returned to
normal by week 11 though the trajectory of the changes
suggests that they might eventually have done so [73].
Repeat infection with the homologous P. vivax strain,
whether due to reinfection, recrudescence or relapse, during
the period of parasite tolerance may result in a transient rise
in parasitaemia but rarely recurrent or exacerbated symp-
toms [142-144]. Homologous re-exposure after an extended
period of parasite exposure (approximately 6 months for
the St Elizabeth strain [141]) from untreated or inad-
equately treated primary infection, relapse or reinfection
results in neither patent parasitaemia nor clinical symptoms
[142,143,145-148]. Since homologous re-exposure in toler-
ant or immune individuals causes little non-specific im-
mune system activation, the haematological effects of this
are likely to be minimal.
Heterologous immunity however, is weak and exposure
to a new strain following primary infection will usually re-
sult in clinical malaria with non-specific immune system
activation, recurrent symptoms and presumably a repeat
haematological insult [144,149]. If this occurs before an
individual’s haemoglobin concentration has returned to
normal following primary infection, the haematological
effects are likely to be additive though direct evidence sup-
porting this postulate is limited [33,72,150]. The likelihood
Figure 2 Mean haemoglobin concentration in relation to parasitaemia in patients with syphilis treated with induced P. vivax infections
(98 with the St Elizabeth strain, 11 with the Chesson strain and 2 with the Korean strain). Reproduced with permission from Collins WE,
et al. [73].
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occurs before complete haematological recovery, is a func-
tion of, among other things, the relapse pattern of local
P. vivax strains and the entomological inoculation rate,
both of which are also likely to affect the rate of genetic re-
combination and hence parasite population diversity [151].
In endemic regions, a high proportion of P. vivax
relapses are known to be caused by heterologous strains
(with regard to the previous vivax infection) [152,153].
This is likely to be particularly common in areas with
relatively intense P. vivax transmission and/or extensive
parasite strain diversity. In such regions, there will also
be a greater chance of simultaneous inoculation of two
different strains of P. vivax which has been shown to
cause deficient homologous immunity and therefore pre-
sumably greater susceptibility to the haematological
effects of future homologous infection [154].
Different P. vivax strains have markedly different
relapse patterns and in some instances may not even
cause a primary infection [34,141,155]. In tropical
regions, relapses tend to occur regularly every three to
four weeks and rarely persist for more than four years
from the time of initial inoculation [33]. In temperate
climes, the period between relapses may be significantly
longer and more variable with some strains showing a
bimodal frequency pattern [33]. Tropical strains with
short relapse intervals will be more likely to cause repeat
blood stage infection before complete haematological re-
covery has occurred and may therefore be expected to
have the greatest haematological impact.The virulence of an individual parasite strain may also
modulate its haematological effects. There is some evi-
dence that the Chesson strain causes fever at lower para-
sitaemia than other strains and therefore that it may be
more immunogenic [156]. In 1947, Whorton and collea-
gues described the anaemia associated with this strain as
“striking” stating that “after the second week of malaria [in
malariatherapy patients], it was difficult to maintain
patients’ erythrocyte count above 2 million per cmm
[corresponding to a haemoglobin concentration of ap-
proximately 6 g/dL] in spite of frequent erythrocyte
transfusions” [156].
Given the aforementioned evidence, one might predict
that the severest haematological impact of vivax malaria
would be seen in tropical regions with high entomo-
logical inoculation rates and virulent circulating strains.
These features are perhaps best exemplified by P. vivax
on the island of New Guinea where the frequently
relapsing Chesson strain is endemic and local popula-
tions experience particularly severe haematological im-
pairment from vivax malaria [14-16,27]. In these regions,
broad anti-disease immunity to all circulating parasite
strains is also likely to develop more rapidly and there-
fore the haematological burden of vivax malaria will be
most heavily skewed to very young children [30].
Most populations at risk of P. vivax infection are also
exposed to P. falciparum and co-infection (not necessarily
patent) with these two species is common [150,157-159]. In
Thailand, mixed infection with P. falciparum and P. vivax
has been shown to attenuate the risk of severe anaemia
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degree of cross-species immunity [70,160-162]. Recent
work has shown that in Papua New Guinea and Papua,
Indonesia, mixed infection causes more severe haemato-
logical impairment than infection with either species alone
[14,16,27]. The explanation for these opposing findings
probably lies in the different transmission dynamics in these
regions. In Thailand, severe falciparum malaria is usually
the result of a single, fulminant infection in a non-immune
individual and therefore earlier induction of suppressive
non-specific immunity provided by coincident P. vivax in-
fection, however minor, is likely to have a protective effect.
In New Guinea, where transmission is more intense, severe
anaemia in those older than one year is more likely to be
the result of repeated or continuous infections due to either
species. In this situation, the haematological effects of infec-
tion with both species are more likely to be additive and
any immunomodulatory effects relatively minor.
Effects of anti-malarial treatment
Early treatment of malaria can truncate the impending
reduction in haemoglobin and accelerate haematological
recovery [70,163,164]. Despite the overall benefits of
treatment, haemoglobin typically falls slightly following
initiation of an anti-malarial drug reaching a nadir be-
tween days three to 7 following treatment [70,165]. Data
are sparse but there is some evidence that this initial fall
may be less pronounced following treatment of vivax
malaria with chloroquine (which gives faster clinical and
parasitological responses against sensitive strains) com-
pared with either sulfadoxine + pyrimethamine or chlor-
proguanil + dapsone [165]. The artemisinin derivatives
cause an extremely rapid reduction in P. vivax parasite
biomass. They also temporarily reduce red blood cell
production [166-168]. In falciparum malaria, evidence
suggests that the haematological benefit of the greater
efficacy of the artemisinin drugs negates or outweighs
the detrimental effects of this bone marrow suppression
[169,170]. The only published comparative assessment of
the acute haematological effects of treatment with an
artemisinin derivative in patients with vivax malaria
showed that artesunate + pyronaridine was associated
with a greater mean reduction in haemoglobin at days 3
and 7 when compared with chloroquine alone, although
no tests of statistical significance were given [167].
Complete removal of blood stage parasites following
blood schizontocidal treatment allows faster haemato-
logical recovery (pre-infection haemoglobin concentra-
tions are generally achieved in approximately 4–5 weeks
following effective treatment [70,163,171,172]) but
reduces total parasite exposure and hence limits the de-
velopment of homologous immunity [146]. Treated indi-
viduals are therefore more likely to develop clinical
malaria with significant haematological impairmentfollowing repeat homologous infection [146,148,173].
Highly efficacious blood schizontocidal regimens con-
taining slowly eliminated drugs (such as chloroquine,
piperaquine or mefloquine) minimize the risk of recru-
descence and also provide extended post-treatment
prophylaxis against recurrent infection, allowing more
time for full haematological recovery [5,150,163,174,175].
The haematological benefit of the long elimination half-
life is likely to be greatest in equatorial regions where
P. vivax strains relapse as often as every three weeks.
Plasmodium vivax has developed high-grade resistance
to chloroquine in parts of Oceania, Asia, Africa and Latin
America [4,5] and sulfadoxine +pyrimethamine in parts of
South-East Asia [176]. Clinically, drug resistance is mani-
fest by delayed parasite clearance times, an increased like-
lihood of incomplete parasite clearance and subsequent
recrudescence as well as a shorter period of post-treatment
prophylaxis against early recurrence [5]. These factors are
likely to result in a greater haematological insult associated
with the initial infection (as demonstrated in P. falciparum
malaria [70,164,177]) but may facilitate earlier develop-
ment of anti-disease immunity.
Primaquine is a hypnozoitocidal drug that, if administered
correctly, can prevent P. vivax relapses and thus reduce the
total haematological impact of a given infection. Unfortu-
nately this medication has the potential to cause lysis of old
red blood cells in all patients, but particularly those with
glucose-6-phosphate dehydrogenase deficiency [178,179].
G6PD deficiency is the most common heritable enzymopa-
thy in the world, with a prevalence ranging from 7.5% in
Africa as a whole to 2.9% in the Pacific [180]. Although
G6PD deficiency increases the susceptibility of erythrocytes
to oxidative damage this alone is not sufficient to account
for primaquine-induced haemolysis [181,182]. Generally,
the more severe the enzyme deficiency, the greater the se-
verity of haemolysis [178,179]. Individuals who have less
than 10% of normal enzyme activity are at risk of life-
threatening haemolysis after as little as one dose of prima-
quine [183] whereas those with milder variants may have
negligible effects [178]. Weekly, as opposed to daily, dosing
schedules mitigate primaquine-induced haemolysis [184]
whilst retaining efficacy [185] though adherence to such
regimens is likely to be poor unless therapy is supervised.
In mildly deficient individuals, continuous daily primaquine
dosing causes acute but self-limited haemolysis for approxi-
mately 10 days followed by reactive reticulocytosis and
haematological recovery as the population of old, suscep-
tible, red blood cells is replaced by young erythrocytes
[184]. Since this is not an immunological phenomenon,
repeat challenge with primaquine after a period of time in
such patients causes equally severe haemolysis [179]. In
severely deficient patients, haemolysis is progressive and
can have a fatal outcome unless primaquine therapy is
stopped and blood transfusion given [186,187].
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The impact of Plasmodium vivax infection on haemoglobin
concentration varies from negligible to dramatic [10,14-
16,188,189]. The clinical consequences of the reduction in
haemoglobin depend on the haemoglobin concentration
prior to infection. For example, an absolute reduction of
2 g/dL would be more likely to have dramatic conse-
quences if the initial haemoglobin was 6 g/dL than if it was
12 g/dL.
In Papua New Guinea, 1.6% of children under 5 years of
age presenting to rural health clinics for treatment of vivax
malaria were severely anaemic (haemoglobin <5 g/dL) [14].
Across the border in Indonesian Papua, 22% of patients of
all ages who were admitted to hospital with vivax malaria
fulfilled criteria for severe anaemia [16]. In the D’Entrecas-
teaux Islands off Papua New Guinea, a cross-sectional
survey of children between 0 and 6 years of age showed that
the mean haemoglobin in those with P. vivax parasitaemia
was 8.7 g/dL, 0.3 g/dL lower than the equivalent value for
those infected with P. falciparum [190]. In contrast, on the
Thai-Myanmar border, less than 0.2% of patients presenting
for treatment of vivax malaria were severely anaemic [189].
Although the spectrum of anaemia seen with vivax infec-
tion is reasonably well documented, the clinical, develop-
mental, and socioeconomic consequences are largely
unknown. Severe anaemia in isolation is associated with a
~2-fold increased risk of death in African children with fal-
ciparum malaria and has an even higher mortality when
combined with other manifestations of severe disease such
as cerebral malaria or respiratory distress [129]. Severe an-
aemia of any cause in hospitalized children under five years
has been associated with a case fatality of between 2% and
29.3% and moderate or severe anaemia has been associated
with a maternal case fatality of between <1% and >50% in
hospital-based studies [191,192].
Population-based estimates of mortality in severely an-
aemic individuals with vivax malaria have not been estab-
lished but recent studies from Latin America, New Guinea
and the Indian subcontinent have identified deaths in
patients with severe vivax anaemia [10,15-17]. The authors
did not establish the extent to which anaemia contributed
to those deaths.
Anaemia caused by vivax malaria is associated with re-
quirement for blood transfusion [188,189]. Screening of
blood products for pathogens is well known to be in-
complete in many low and middle income countries and
therefore has a significant attendant risk of pathogen
transmission [193]. For example, in Sub-Saharan Africa,
estimates for the risk of transfusion-associated infection
with HIV, hepatitis B and hepatitis C are 1, 4.3 and 2.5
infections per 1,000 units of blood respectively [194].
Pregnant women with haemoglobin concentrations
under 8 g/dL in Papua New Guinea were at 2.4-fold
higher risk of delivering a low birth weight baby thannon-anaemic mothers [195]. In this study, primigravidae
with anaemia and parasitaemia at the time of delivery
had the greatest risk of low birth weight [195]. Although
vivax malaria is endemic in Papua New Guinea, attribu-
tion of these effects specifically to this species is not pos-
sible [195]. In Papua, Indonesia, P. vivax parasitaemia at
delivery is associated independently with an increased
risk of moderate anaemia and a mean reduction in birth
weight of 108 g [35].
Although evidence is lacking it seems plausible that
severe vivax anaemia may reduce resilience to other
infectious and non-infectious diseases and therefore may
be associated with indirect mortality. In 1938, Swellen-
grebel and de Buck reported that 62 (7.7%) of a series of
807 patients with syphilis who were treated with induced
P. vivax infections subsequently died; those with other
comorbidities were at particularly great risk [196].
Chronic or repeated episodes of malarial anaemia due
to any Plasmodium species have been associated with
adverse effects on physical and cognitive development as
well as school attendance; all of which may be exacer-
bated by concomitant malnutrition [197-202]. Again,
whether these outcomes are generalizable to vivax
malaria, and more specifically the haematological effects
of this species, is unknown.
Conclusions
Haematological morbidity associated with P. vivax infection
is greatest in young children, especially in tropical countries
such as Papua New Guinea and Eastern Indonesia where
transmission is intense and local parasite strains relapse
very frequently. In these regions, vivax malaria is commonly
associated with severe anaemia both in the health care and
community setting. The haematological effects of vivax
malaria are likely to have complex interactions with gastro-
intestinal helminth infection, haemoglobin and red blood
cell abnormalities and malnutrition.
Removal of uninfected red blood cells is a particularly
important mechanism of anaemia in acute vivax malaria.
Plasmodium vivax-infected red blood cells are minimally
adherent and are more deformable than P. falciparum-
infected erythrocytes resulting in relatively little red blood
cell sequestration in the microvasculature and marrow
sinuses and passage of a greater proportion of red cells
through the spleen and other reticuloendothelial organs.
The role of the spleen in the pathogenesis of vivax anaemia,
particularly the removal of uninfected red blood cells, is an
important area for future research (Figure 3).
As the global control and elimination of malaria pro-
gresses, P. vivax is set to become the dominant Plasmodium
species [4,203], yet the health, developmental and socioeco-
nomic consequences of vivax malaria and vivax–associated
anaemia have received very little attention. Severe vivax
anaemia may cause significant morbidity and indirect
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tious and non-infectious comorbidities, obstetric complica-
tions and requirement for blood transfusion (with
attendant risk of blood-borne pathogen transmission).
Early treatment with an efficacious blood schizontocide can
reduce the initial fall in haemoglobin associated with vivax
infection and thus help to prevent adverse outcomes asso-
ciated with severe anaemia. Reliable prevention of recur-
rent haematological insults caused by relapses will requireOutstanding questions on the anaemia of Plasmodium viva
• Why are young children particularly susceptible 
• Is severe vivax-associated anaemia typically a re
• What is the haematological effect of recurrent P.
• What are the haematological effects of coinfectio
• What is the relationship between heritable haemo
• What is the relationship between malnutrition an
• Where does red blood cell removal in vivax mala
• What is the mechanism of removal of uninfected
age? 
• Is the ratio of uninfected to infected red blood ce
compared with adults? 
• Why is the proportional removal of uninfected re
with falciparum malaria? 
• What is the time course of red blood cell remova
• What is the role of the spleen in the anaemia of v
• What is the association between vivax anaemia a
• What are the health and developmental conseque
• What are the socioeconomic consequences of viv
• What are the haematological benefits of a longer
recrudescence and relapse? 
• Is the bone marrow suppression associated with a
• What is the incidence of severe haemolysis follo
phosphate dehydrogenase deficiency? 
• At what level of glucose-6-phosphate dehydroge
• What is the safety of primaquine in infancy? 
Figure 3 Outstanding questions on the anaemia of Plasmodium vivaxhypnozoitocidal therapy. Primaquine is the only licensed
hypnozoitocidal agent available and can exacerbate haem-
olysis in individuals with G6PD deficiency. Policymakers
need to weigh the potential benefits of this drug against the
risks based on the local prevalence of this enzymopathy as
well as the availability of G6PD testing. Vivax-associated
anaemia is an important public health concern that under-
scores the importance of reducing global transmission of
P. vivax.x malaria 
to the anaemia of vivax malaria? 
sult of fulminant, chronic or recurrent disease? 
 vivax relapses? 
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